Cerebral edema

Global Bioactive Peptide Market Report 2022: Increasing R&D by Leading Players Driving Growth - ResearchAndMarkets.com

Retrieved on: 
fredag, november 11, 2022
Biotechnology, Health, Other Health, Pulmonary edema, Cerebral edema, Entwicklung und Erprobung von Leichtflugzeugen, Industry, Rheumatoid arthritis, US, Region, Protein, Conditional sentence, Cardiovascular disease, Cancer, Peptide, Research, Food, Market share, CAGR, Infection, Diabetes, Par value, Growth, Short bowel syndrome, Marketing, Nutrient, Inhalation, Fine chemical

The "Bioactive Peptide Market, by Source, by Therapeutic Area, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bioactive Peptide Market, by Source, by Therapeutic Area, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The bioactive peptides are ingredients that provide nutritive value to the food by adding protein and other important nutrients.
  • Therefore, bioactive peptides are used as treatment therapy for most of the functional disorders such as irritable bowel disease, which is expected to drive the market growth.
  • Increasing research and development by key market players for the treatment of pulmonary edema and rheumatoid arthritis is expected to drive growth of the global bioactive peptide market over the forecast period.

Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
torsdag, november 10, 2022
Oncology, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Investor, Cerebral edema, Private Securities Litigation Reform Act, Retinitis pigmentosa, Review, Allergic conjunctivitis, Marketing, Ocular hypertension, RASP, U.S. Securities and Exchange Commission, Retinal detachment, Conversation, Nasdaq, Uveitis, Research, Risk, Financial condition report, COVID-19, Therapy, Type, SEC, Failure, Annual report, Safety, Securities Exchange Act of 1934, Inflammation, Toxicity, Patient, Pain, Growth, CEO, Analysis, Result, Security (finance), NDA, Duane syndrome, FDA, Pharmaceutical industry, Medical device, Schirmer, Facebook

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2022.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2022.
  • In addition to efficacy data, Aldeyra plans to submit up to 12 months of reproxalap safety data.
  • Pending the results of the pre-NDA meeting, NDA submission may occur as soon as the end of 2022.
  • ET today to discuss recent corporate highlights and financial results for the quarter ended September 30, 2022.

Vitreous Retina Macula Consultants of New York Ophthalmologists Awarded Newsweek Best Eye Doctors of 2022

Retrieved on: 
fredag, oktober 28, 2022
Eye, Consultant, Ear, Thomas Jefferson University, Drug development, Editorial board, Medical Center, Optometry, Clinical professor, Diagnosis, LuEsther Mertz, NewYork-Presbyterian Hospital, University School, Physician, Sue Spaid, Research, Muhlenberg College, Manhattan Eye, Ear and Throat Hospital, Lawrence Yannuzzi, Patient, Macular degeneration, Multimedia, Diabetic retinopathy, Association, Association for Research in Vision and Ophthalmology, Saint Vincent, Editing, Population, New York University Grossman School of Medicine, Private practice, Book, Publication, NEW, Hospital, Cerebral edema, Solution, Pharmaceutical industry, MD, Ophthalmology, Retina, Newsweek

NEW YORK, Oct. 28, 2022 /PRNewswire/ -- According to Newsweek, demand for professional eye care in the U.S. is expected to increase significantly in the coming years as the population ages.

Key Points: 
  • NEW YORK, Oct. 28, 2022 /PRNewswire/ -- According to Newsweek, demand for professional eye care in the U.S. is expected to increase significantly in the coming years as the population ages.
  • Each year, they compile a list of America's Best Eye Doctors to help people find the right professional for their eye needs and make top eye care accessible to everyone.
  • "We are honored, as a practice, to have three of our Ophthalmologists included in this prestigious list of America's Best Eye Doctors with Newsweek," Spaide said.
  • The group of ophthalmologists at Vitreous Retina Macula Consultants of New York are internationally known leaders in diagnosing and treating retinal diseases, known as the top New York experts and among the best-rated retina specialists in NYC.

Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology

Retrieved on: 
onsdag, september 28, 2022
Storm, Adult, American Academy, Lens, Aphakia, Cataract, American Academy of Ophthalmology, Lists of diseases, Ophthalmology, Patient, Clinical trial, U.S. Securities and Exchange Commission, Exercise, Technology, Perception, Muscular dystrophy, Biostatistics, Risk, Temperature, EDOF, Amblyopia, Annual general meeting, Life, Rotation, GLARE, Cerebral edema, Johnson & Johnson, Visual acuity, Annual report, Direction, Doctor of Philosophy, Surgeon, Behavior, Color, MD, Emmetropia, Language interpretation, Medtech, IOL, Presbyopia, Severe cognitive impairment, EMEA, Security (finance), Light, Endophthalmitis, Health, AAO, Vision, LinkedIn, Johnson & Johnson Vision, Astigmatism, Private Securities Litigation Reform Act, Eye, Use, Diagnosis, Fine chemical, Telescopic sight, Pharmaceutical industry, Facebook

IRVINE, Calif., Sept. 28, 2022 /PRNewswire/ -- Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight, TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light performance across the PC-IOL category.1,2,3 The InteliLight portfolio will be on display at the 2022 American Academy of Ophthalmology's Annual Meeting (AAO) in Chicago, Sept. 30-Oct. 3.

Key Points: 
  • To learn more about the InteliLight portfolio, please visit https://www.jnjvisionpro.com/intelilight in the U.S.
    At Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, we have a bold ambition: to change the trajectory of eye health worldwide.
  • Visit us at jjvision.com , follow @JNJVision on Twitter , Johnson & Johnson Vision on LinkedIn , and @JNJVision on Facebook .
  • Neither Johnson & Johnson Vision, the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
  • **Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

Retrieved on: 
onsdag, september 21, 2022
Kepler, Headache, ASX, Safety, Radiation, Brain, FDA, Food, Glioblastoma, Diarrhea, Australian Securities Exchange, Hiccup, Principal, MTR, LinkedIn, Population, Company, TLX, TGA, Degenerative disease, GBM, Survival, Patient, Platelet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Insomnia, Gallium, Cerebral edema, Diagnosis, Neoplasm, Fatigue, Lymphocyte, Swelling, EBRT, Pharmaceutical industry, Medical imaging, Telix

The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM.

Key Points: 
  • The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM.
  • Final data up to the completion of the post-study follow-up period confirms the study has met its primary objective, demonstrating the safety and tolerability profile of TLX101 at the dosing range tested.
  • The study also delivered encouraging preliminary efficacy data for further evaluation, demonstrating a median overall survival (OS) of 13 months from the initiation of treatment in the recurring setting, or 23 months from initial diagnosis.
  • We can reconfirm that TLX101 has demonstrated safety and tolerability profile and encouraging early efficacy data.

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

Retrieved on: 
onsdag, september 21, 2022
Kepler, Headache, ASX, Safety, Radiation, Brain, FDA, Food, Glioblastoma, Diarrhea, Australian Securities Exchange, Hiccup, Principal, MTR, LinkedIn, Population, Company, TLX, TGA, Degenerative disease, GBM, Survival, Patient, Platelet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Insomnia, Gallium, Cerebral edema, Diagnosis, Neoplasm, Fatigue, Lymphocyte, Swelling, EBRT, Pharmaceutical industry, Medical imaging, Telix

The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM.

Key Points: 
  • The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM.
  • Final data up to the completion of the post-study follow-up period confirms the study has met its primary objective, demonstrating the safety and tolerability profile of TLX101 at the dosing range tested.
  • The study also delivered encouraging preliminary efficacy data for further evaluation, demonstrating a median overall survival (OS) of 13 months from the initiation of treatment in the recurring setting, or 23 months from initial diagnosis.
  • We can reconfirm that TLX101 has demonstrated safety and tolerability profile and encouraging early efficacy data.

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

Retrieved on: 
tisdag, september 20, 2022
Cerebral edema, Risk, Therapy, Inflammation, Traumatic brain injury, Accident, CGMP, U.S. Securities and Exchange Commission, Organization, NEW, IND, Data management, Private Securities Litigation Reform Act, Partnership, Stroke, HT, Patient, Military personnel, Annual report, Medical writing, TBI, Head injury, Drug development, General manager, Caregiver, NASDAQ, Investigational New Drug, Biostatistics, Biotechnology, Pharmaceutical industry, Hoth, Coronavirus

NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation. HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI"). HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.

Key Points: 
  • HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI").
  • "We are pleased to have been selected by Hoth Therapeutics, Inc. to support their important goal of developing a ready-to-use drug-device combination product for the treatment and/or prevention of secondary brain injury.
  • Altasciences' purpose is to help companies like Hoth Therapeutics research and develop potentially life-saving therapeuticsas safely and as fast as possible."
  • "Hoth is excited to announce this partnership and next milestone in our development of HT-TBI," stated Dr. Stefanie Johns, Chief Scientific Officer.

Alzheon Appoints Glenn Pauly as Head of Commercial

Retrieved on: 
tisdag, september 20, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cerebral edema, Precision medicine, Neurodegeneration, Safety, Neurotoxicity, Plaque, Risk, Brain, MD, AD, Food, Biomarker, APOE4, Alzheimer's disease, Ageing, Population, Health, National Institute on Aging, NDA, Head, Patient, Â, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Johnson & Johnson, Technology, AstraZeneca, Pathology, Commercial, Doctor of Philosophy, Fast Track, Caregiver, Dementia, Biogen, National Institute, Pharmaceutical industry, Medical imaging, Genentech, Alzheon

Alzheon, Inc. , a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimers disease (AD) and other neurodegenerative disorders, today announced the appointment of Glenn E. Pauly as Head of Commercial.

Key Points: 
  • Alzheon, Inc. , a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimers disease (AD) and other neurodegenerative disorders, today announced the appointment of Glenn E. Pauly as Head of Commercial.
  • Mr. Pauly brings to Alzheon more than 20 years of commercial launch experience in the biopharmaceutical industry.
  • He has extensive experience with launching disease-modifying agents in multiple therapeutic areas working across multiple commercial functions including sales, account management and market access.
  • It is an incredibly exciting time to be joining Alzheon, said Mr. Pauly.

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Retrieved on: 
tisdag, september 20, 2022
Neurology, Biometrics, Biotechnology, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Cerebral edema, Good laboratory practice, Plasma, Neurodegeneration, Precision medicine, Safety, Neurotoxicity, Plaque, Ageing, Risk, Brain, MD, Disease, Biomarker, Food, APOE4, MRI, Population, National Institute on Aging, Genotype, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ADAS, CEO, Technology, University of Gothenburg, Female, Pathology, Culture Collection (University of Gothenburg), Doctor of Philosophy, Fast Track, Dementia, Neuron, University, National Institute, Cerebrospinal fluid, Medical imaging, Pharmaceutical industry, Alzheimer's disease, Alzheon

In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.

Key Points: 
  • In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.
  • APOE4 genotype, the leading risk factor for AD after aging, is associated with a several-fold higher brain burden of neurotoxic amyloid oligomers.
  • P-tau181 levels rise with AD progression and clinical deterioration of patients, and have been shown to fall in response to clinically effective disease modifying treatments in Alzheimers.
  • Our lead Alzheimers clinical candidate, ALZ-801 (valiltramiprosate) , is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD.

Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

Retrieved on: 
tisdag, september 6, 2022
National, Diabetic retinopathy, CEO, Cerebral edema, Safety, Caregiver, Acta Ophthalmologica, Severe cognitive impairment, Doctor of Philosophy, Disease, Injection, DME, NIH, Reading, Quality of life, ACTA, MD, CMT, Retinal, Population, Edema, Universitate metro station, Dexamethasone, Diabetes, Data, Patient, Pharmaceutical industry, Ophthalmology, Massilia oculi

The publication is accessible on the National Institutes of Health (NIH) website here ( https://pubmed.ncbi.nlm.nih.gov/35848336/ ).

Key Points: 
  • The publication is accessible on the National Institutes of Health (NIH) website here ( https://pubmed.ncbi.nlm.nih.gov/35848336/ ).
  • Approximately 37 million people are affected by DME worldwide, representing around 7% of the large and growing diabetes patient population.
  • Although treatment options currently exist, all of them are invasive (injections or implants) and represent a significant burden for patients and caregivers.
  • With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide.